|
|
||||||||
From the Departments of Neuro-oncology/Neurology (Drs. de Wit, Sillevis Smitt, and van den Bent), Radiology (Dr. de Bruin), and Radiotherapy (Dr. Eijkenboom), Daniel den Hoed Cancer Center/Erasmus Medical Center, Rotterdam, The Netherlands.
Address correspondence and reprint requests to Dr. M.J. van den Bent, Department of Neuro-oncology/Neurology, Daniel den Hoed Cancer Center/Erasmus Medical Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands; e-mail: m.vandenbent{at}erasmusmc.nl
To determine the frequency of progressive MRI lesions shortly after radiotherapy for glioma with spontaneous improvement or stabilization, the authors studied a cohort of patients treated within two prospective phase III trials with radiotherapy only. In 9 out of 32 patients, the first post-radiotherapy MRI showed progressive enhancement. In 3 of these 9 the MRI improved or stabilized for 6 months without additional treatment. The authors conclude that patients with progressive lesions within 3 months after radiotherapy should not be eligible for phase II trials on recurrent glioma.
Received December 4, 2003. Accepted in final form April 13, 2004.
Related Article
Neurology 2004 63: 407.
This article has been cited by other articles:
![]() |
M. C. Chamberlain Pseudoprogression in Glioblastoma J. Clin. Oncol., September 10, 2008; 26(26): 4359 - 4359. [Full Text] [PDF] |
||||
![]() |
R. I. Jakacki, A. Yates, S. M. Blaney, T. Zhou, R. Timmerman, A. M. Ingle, L. Flom, M. D. Prados, P. C. Adamson, and I. F. Pollack A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood Neuro-oncol, August 1, 2008; 10(4): 569 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Brandes, E. Franceschi, A. Tosoni, V. Blatt, A. Pession, G. Tallini, R. Bertorelle, S. Bartolini, F. Calbucci, A. Andreoli, et al. MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients J. Clin. Oncol., May 1, 2008; 26(13): 2192 - 2197. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Brandes, A. Tosoni, F. Spagnolli, G. Frezza, M. Leonardi, F. Calbucci, and E. Franceschi Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology Neuro-oncol, January 1, 2008; 10(3): 361 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Chamberlain, W. B. Pope, and T. Cloughesy MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology, December 12, 2006; 67(11): 2089 - 2089. [Full Text] [PDF] |
||||
![]() |
W. Wick and A. Kaufmann Glioblastoma: what's ischemia got to do with it? Neurology, November 14, 2006; 67(9): 1540 - 1541. [Full Text] [PDF] |
||||
![]() |
F. Schmidt, J. Fischer, U. Herrlinger, K. Dietz, J. Dichgans, and M. Weller PCV chemotherapy for recurrent glioblastoma Neurology, February 28, 2006; 66(4): 587 - 589. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |